Peking University Cancer Hospital & Institute: all 266 studies

Page 2 of 3. Open to participants first (128), then studies with results posted, then the rest; newest registration first within each.

• Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)RecruitingNCT06229041Phase 3
• Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct CarcinomaRecruitingNCT06211114Phase 2
• Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal CancerRecruitingNCT06209099Not applicable
• Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabRecruitingNCT06141265Phase 2
• Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung CancerRecruitingNCT06081777
• Registry Study in MSI/dMMR Solid TumorsRecruitingNCT06004713
• KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaNot yet recruitingNCT05985707Phase 2
• KN 046 Plus Regorafenib in MSS Metastatic Colorectal CancerRecruitingNCT05985109Phase 2
• Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCCRecruitingNCT05917431Phase 2
• To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver MetastasesNot yet recruitingNCT05889325
• The Value of MRI in Assessing the Status of Retroperitoneal Resection Margin in Colon CancerRecruitingNCT05859581Not applicable
• Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral MelanomaRecruitingNCT05789043Phase 3
• Cadonilimab in the Treatment of Advanced Soft Tissue SarcomaNot yet recruitingNCT05656144Phase 2
• Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell LymphomaRecruitingNCT05590221Phase 2
• Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid TumorsRecruitingNCT05579275Early Phase 1
• Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon CancerRecruitingNCT05529615Not applicable
• Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral MelanomaRecruitingNCT05512481Phase 2
• Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced MelanomaRecruitingNCT05478473Not applicable
• CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid TumorsRecruitingNCT05436093Not applicable
• Nectin-4 Targeting ADC Probe for PET Imaging in Solid TumorsNot yet recruitingNCT05322512Not applicable
• Nectin-4 Specific LMW PET Probe Imaging in Urothelial CarcinomaRecruitingNCT05321316Not applicable
• A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerRecruitingNCT05104788Phase 2
• PD-L1 Targeting Molecular Imaging of Solid TumorsRecruitingNCT04629326Not applicable
• 68Ga-ICAM-1pep PET/CT in Cancer PatientsRecruitingNCT04596670Early Phase 1
• Research for the Molecular Imaging of the HER2 Targeting TracerRecruitingNCT04547309Not applicable
• Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II StudyRecruitingNCT04462965Phase 2
• Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric AdenocarcinomaRecruitingNCT04047953Not applicable
• The Multi-Center Study of Shear Wave Elastography on Thyroid NodulesAvailableNCT02937467
• Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)CompletedNCT02878057Phase 2Results posted
• Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal CancerActive, not recruitingNCT07745322
• Preoperative ROS1-TKI Therapy for ROS1 Fusion-Positive Locally Advanced Lung AdenocarcinomaCompletedNCT07700836
• Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast CancerActive, not recruitingNCT07018427
• Study on the Applicability of CCR Criteria in Rectal CancerCompletedNCT06794099
• Attitudes and Technical Maneuvers Regarding Enterostomy Management and Stoma Creation Among SurgeonsCompletedNCT06735729
• First Human Trial of Targeting MDM2/MDMX PET ImagingCompletedNCT06443762Early Phase 1
• Dynamic ctDNA Detection for Colorectal Cancer Liver MetastasesCompletedNCT06404593
• Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging ProbeCompletedNCT06203119Phase 1
• HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell CarcinomaCompletedNCT06184841Phase 1
• KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadeActive, not recruitingNCT06099821Phase 2
• Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide TherapyStatus unknownNCT05985278Early Phase 1
• Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABCCompletedNCT05969184Phase 2
• the Beijing Randomized Study Of Prostate Cancer ScreeningStatus unknownNCT05961514Not applicable
• Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)Status unknownNCT05955209Phase 2
• Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical SignificanceCompletedNCT05933863
• The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver MetastasesStatus unknownNCT05877001Phase 2
• The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular CarcinomaStatus unknownNCT05862181
• Computation Prediction of Drug Response Based on Omics DataStatus unknownNCT05833802
• Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric AdenocarcinomaStatus unknownNCT05816863
• PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid TumorStatus unknownNCT05803746Not applicable
• Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC PatientsCompletedNCT05758116Phase 2
• Outcomes of Endoscopic Operation in COVID-19 Infection: Cohort Study.Status unknownNCT05685914
• Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast CancerStatus unknownNCT05577442Phase 2
• Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in LymphomaStatus unknownNCT05411250
• Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line TherapyStatus unknownNCT05406206Phase 2
• Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in LymphomasStatus unknownNCT05390632
• A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung CancerStatus unknownNCT05380024Phase 2
• Establishment of MRI Model for pTRG in Rectal Cancer With Establishment ofActive, not recruitingNCT05374044
• Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT MutStatus unknownNCT05274438Phase 2
• RSYR for Fatigue Reduction in Cancer Fatigue Caused by ChemotherapyActive, not recruitingNCT05229029Phase 2
• Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With TrastuzumabStatus unknownNCT05188495
• PD-L1 Targeting Nanobody Probe for PET Imaging of Solid TumorStatus unknownNCT05156515Not applicable
• Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung CancerStatus unknownNCT05132218
• Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05104801Phase 2
• Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver MetastasisStatus unknownNCT05070221Phase 1
• Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver MetastasisStatus unknownNCT05068453Phase 1
• To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced MelanomaStatus unknownNCT05051865Phase 2
• cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCCStatus unknownNCT05025592
• The Performance of Multi-tracer Multimodality PET in LymphomaStatus unknownNCT05004961
• 68Ga-grazytracer PET/CT of Tumor Responses to ImmunotherapyCompletedNCT05000372Phase 1/2
• CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal TumorsActive, not recruitingNCT04883970Not applicable
• Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsStatus unknownNCT04764084Phase 1
• Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal CancerStatus unknownNCT04750772Not applicable
• The Role of TCM on ERAS of Rectal Cancer PatientsStatus unknownNCT04749381Phase 2
• [Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer PatientsActive, not recruitingNCT04693169Not applicable
• Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLCStatus unknownNCT04629027
• Lenvatinib and Pembrolizumab in Resectable Mucosal MelanomaStatus unknownNCT04622566Phase 2
• A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.Status unknownNCT04606303Phase 2
• TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCCStatus unknownNCT04597970Phase 2
• 99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer PatientsStatus unknownNCT04591652Not applicable
• PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate CancerActive, not recruitingNCT04560725Not applicable
• Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRIStatus unknownNCT04555642
• The Molecular Imaging Research of F-18 Labeled DX600 PET ProbeStatus unknownNCT04542863Not applicable
• The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04542837Phase 2
• Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04479527Phase 2
• Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in PatientsCompletedNCT04422457Not applicable
• To Identify KRAS Gene and Safe Margin in Association With Outcome in Colorectal Liver Metastases Following Ultrasound-guided Radiofrequency AblationStatus unknownNCT04417010
• Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant ChemotherapyStatus unknownNCT04408859
• Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal CancerStatus unknownNCT04405206
• Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral MelanomaStatus unknownNCT04397770Phase 2
• Positron Nuclide Labeled NOTA-FAPI PET Study in LymphomaStatus unknownNCT04367948Not applicable
• The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of MelanomaStatus unknownNCT04357509Phase 1
• Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on NeoantigenStatus unknownNCT04340401Phase 2
• Research for the Molecular Imaging of the PD-L1 Targeting TracerActive, not recruitingNCT04304066Not applicable
• Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLCStatus unknownNCT04303130Phase 2
• Drug Sensitivity Screening for Gastrointestinal CancerStatus unknownNCT04298489Not applicable
• Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal CancerStatus unknownNCT04296240Phase 2
• A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial CancerStatus unknownNCT04264936Phase 1/2
• Preliminary Study on Eye Features of Patients With Malignant TumorsCompletedNCT04224298
• Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From MelanomaStatus unknownNCT04206358Phase 1
• Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced MelanomaActive, not recruitingNCT04197882Phase 1

← Peking University Cancer Hospital & Institute overview and focus areas